Actualités et Activités de Immunocore
Dirigeants
Voir l'organigramme avec ses 33 principaux dirigeants
Biographies les plus recherchées chez Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- John Bell, Non Executive Chairman of the Board
- Roy Herbst, Non-Executive Director To The Board
Changements de dirigeants chez Immunocore
- William Pao, a rejoint l'entreprise comme Non Executive Director (publié le 27 février 2025).
- Travis Coy qui était Non-Executive Director, devient Executive Vice President, Chief Financial Officer and Head of Corporate Development (publié le 2 janvier 2025).
- Brian Di Donato, Chief Financial Officer and Head of Strategy, quittera l'entreprise le 31 déc. 2024 (publié le 1 septembre 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Immunocore.
Biotechnologie
Immunocore a 2 350 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Johnson & Johnson Innovative Medicine DIA (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Transcarent and Accolade have merged (publié le 9 avril 2025)..
- Kashiv BioSciences vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 7 avril 2025).
- Atsena Therapeutics vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 4 avril 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Immunocore
- Immunocore sur Wikipédia, Google News & Yahoo Finance en 1-click
- Immunocore sur LinkedIn, Twitter & YouTube en 1-click
